Volume 15, Issue 8, Pages 894-904 (July 2014) Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial  Susan J Dutton, MSc, Prof David R Ferry, PhD, Prof Jane M Blazeby, MD, Haider Abbas, MRCP, Asa Dahle-Smith, MBChB, Wasat Mansoor, PhD, Joyce Thompson, FRCP, Mark Harrison, PhD, Anirban Chatterjee, FRCR, Stephen Falk, MD, Angel Garcia-Alonso, MD, David W Fyfe, MD, Richard A Hubner, PhD, Tina Gamble, Lynnda Peachey, BSc, Mina Davoudianfar, BA, Sarah R Pearson, BSc, Patrick Julier, MSc, Prof Janusz Jankowski, PhD, Rachel Kerr, MD, Russell D Petty, MRCP  The Lancet Oncology  Volume 15, Issue 8, Pages 894-904 (July 2014) DOI: 10.1016/S1470-2045(14)70024-5 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile PRO=patient-reported outcome. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Survival Kaplan-Meier plots of overall survival by (A) treatment and (B) performance status, and (C) progression-free survival by treatment. HR=hazard ratio. PS=performance status. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Hazard ratio plot of the treatment effect by prognostic factors for progression-free survival The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 4 Waterfall plots for patients with measurable disease at baseline and 4 weeks, response confirmed at 8 weeks Green=recorded as progressed by 8 weeks, might have been new lesions. Grey=not reported as progressed. RECIST=Response Evaluation Criteria in Solid Tumors. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 5 Mean raw scores for prespecified patient-reported outcomes at all timepoints Higher score equates to better quality of life or more symptoms. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 6 Mean change in health-related quality-of-life outcomes from baseline to 4 weeks Positive values on the functioning scale and negative values on the symptom scale denote benefit from gefitinib compared with placebo. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions